Skip to main content
U.S. flag

An official website of the United States government

Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils

Bibliographic

Year of Publication:
2003
Contact PI Name:
Nibaldo C. Inestrosa
Contact PI Affiliation:
Molecular Neurobiology Unit, P Catholic University of Chile, Santiago, Chile
Co-Authors:
G.V. De Ferrari, M.A. Chacón, M.I. Barría, J.L. Garrido, J.A. Godoy, G. Olivares, A.E. Reyes, A. Alvarez, M. Bronfman
Primary Reference (PubMED ID):
Funding Source:
FONDAP-Biomedicine
Millennium Institute for Fundamental and Applied Biology (MIFAB)
Study Goal and Principal Findings:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, which is probably caused by the cytotoxic effect of the amyloid β-peptide (Aβ). We report here molecular changes induced by Aβ, both in neuronal cells in culture and in rats injected in the dorsal hippocampus with preformed Aβ fibrils, as an in vivo model of the disease. Results indicate that in both systems, Aβ neurotoxicity resulted in the destabilization of endogenous levels of β-catenin, a key transducer of the Wnt signaling pathway. Lithium chloride, which mimics Wnt signaling by inhibiting glycogen synthase kinase-3β promoted the survival of post-mitotic neurons against Aβ neurotoxicity and recovered cytosolic β-catenin to control levels. Moreover, the neurotoxic effect of Aβ fibrils was also modulated with protein kinase C agonists/inhibitors and reversed with conditioned medium containing the Wnt-3a ligand. We also examined the spatial memory performance of rats injected with preformed Aβ fibrils in the Morris water maze paradigm, and found that chronic lithium treatment protected neurodegeneration by rescuing β-catenin levels and improved the deficit in spatial learning induced by Aβ. Our results are consistent with the idea that Aβ-dependent neurotoxicity induces a loss of function of Wnt signaling components and indicate that lithium or compounds that mimic this signaling cascade may be putative candidates for therapeutic intervention in Alzheimer's patients.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
Lithium
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Rat
Model Type:
beta Amyloid Peptide Injection
Strain/Genetic Background:
Not Applicable
Animal Model Notes:
The beta amyloid fibrils used to generate the AD model were pre-formed from human wild-type beta amyloid 1-40 peptide.
In studies using rats, typically the rat weight is reported rather than age. A male Sprague Dawley rat weighing 200g is between 6-8 weeks old.

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Histopathology
Neuronal Loss
Biochemical
beta Catenin
phospho-Glycogen Synthase Kinase 3 beta (phospho-GSK3 beta)
Immunochemistry
Apoptosis
Brain-beta Amyloid Deposits
beta Catenin
Glycogen Synthase Kinase 3 beta (GSK3 beta)
Microscopy
Cell Count
Cell Morphology
Cell Size
Neurite Morphology
Cell Biology
Cell Viability
Cytotoxicity
Axonal Atrophy
Dendritic Atrophy
Neuroprotection-Amyloid Neurotoxicity
Pharmacokinetics
Drug Concentration-Plasma